GERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University

Similar documents
Unmet Needs in the Management of Gastroesophageal Reflux Disease

GERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018

Refractory GERD. Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida

Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI

4/24/2015. History of Reflux Surgery. Recent Innovations in the Surgical Treatment of Reflux

Refractory GERD : case presentation and discussion

Hold the Wrap! There is so much more to be done!

Endoscopic vs Surgical Therapies for GERD: Is it Time to Put down the Scalpel?

Drug Class Monograph

NEGATIVE ENDOSCOPY, What is the Diagnosis and Treatment?

Novel Approaches for Managing Reflux. Marcus Reddy Consultant General and Upper GI surgeon

Options for Gastroesophageal Reflux: Endoluminal. W. Scott Melvin, M.D. Montefiore Medical System and the Albert Einstein School of Medicine

Refractory GERD: What s a Gastroenterologist To Do?

Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors

Guiding Principles. Trans-oral Incisionless Fundoplication (TIF) for GERD: When, Why & How 4/6/18

ACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease

Burning Issues in Gastroesophageal Reflux Disease (GERD)

CYP2C19-Proton Pump Inhibitors

In the Name of God. Refractory GERD

ENDOLUMINAL THERAPIES FOR GERD. University of Colorado Department of Surgery Grand Rounds March 31st, 2008

Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Gastroesophageal Reflux Disease (GERD)

Alimentary Pharmacology & Therapeutics SUMMARY

GERD: Pitfalls and Pearls

Understanding GERD. & Stretta Therapy. GERD (gĕrd): Gastroesophageal Reflux Disease

Treatment Options for GERD or Acid Reflux Disease A Review of the Research for Adults

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group)

Novel Therapy in Gastroesophageal Reflux Disease (GERD)

Electrical neuromodulation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease

GERD: A linical Clinical Clinical Update Objectives

Review article: alternative approaches to the long-term management of GERD

LINX. A new, FDA approved treatment for GERD

Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease where next?

Nexium 24HR Pharmacy Training

Gastroesophageal Reflux Disease, Paraesophageal Hernias &

Drug Class Review Proton Pump Inhibitors

Effective Health Care

Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist

Index. Note: Page numbers of article titles are in boldface type.

Utilisation of surgical fundoplication for patients with gastro-oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013

Relieving Frequent Heartburn Day Through Night

Drug Class Review on Proton Pump Inhibitors

MEDICAL POLICY SUBJECT: MAGNETIC ESOPHAGEAL RING/ MAGNETIC SPHINCTER AUGMENTATION FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD)

GERD: How to. Failures

Disclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.

Committee Approval Date: October 14, 2014 Next Review Date: October 2015

Magnetic Esophageal Ring to Treat Gastroesophageal Reflux Disease (GERD)

QUICK QUERIES. Topical Questions, Sound Answers

Gastroesophageal reflux disease. The case for improving patient education in primary care

MINIMALLY INVASIVE PROCEDURES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)

Approach to Patients with Non-Cardiac Chest Pain

Patient information. Laryngopharyngeal Reflux ( LPR) Ear Nose and Throat Directorate PIF 1423/V4

Reflux of gastric contents, particularly acid, into the esophagus

Drug Class Review on Proton Pump Inhibitors

Putting Chronic Heartburn On Ice


A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?

The STRETTA Procedure

Heartburn is a common symptom among adults in

Nexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.

Role of Endoscopy in Gastroesophageal Reflux Disease

Maximizing Outcome of Extraesophageal Reflux Disease. (GERD) is often accompanied

You May Be at Risk. You are currently taking a proton pump inhibitor (PPI):

GERD. From Clinician to Pharmacologist. Chien-Heng, Shen

Page 1. Objectives. The Role of the Pharmacist as Gatekeeper to the Appropriate Use of OTC PPI Therapy in Frequent Heartburn


MY PATIENT HAS READ THAT HIS PPI S MAY BE TROUBLE. NOW WHAT?

GERD. Gastroesophageal reflux disease, or GERD, occurs when acid from the. stomach backs up into the esophagus. Normally, food travels from the

MINIMALLY INVASIVE PROCEDURES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)

David A. Peura 1,5*, Anne Le Moigne 2, Heather Wassel 3 and Charles Pollack 4

What can you expect from the lab?

Four-Day Bravo ph Capsule Monitoring With and Without Proton Pump Inhibitor Therapy

Disclosures. Heartburn and Barrett s Esophagus. Heartburn and Barrett s Esophagus. GERD is common in the U.S. None

Proton Pump Inhibitors. Description

Review article: immediate-release proton-pump inhibitor therapy potential advantages

Keywords transoral incisionless fundoplication (TIF), EsophyX, extraesophageal GERD symptoms, regurgitation, proton pump inhibitor (PPI), heartburn

For this session on the esophagus, I have selected three conditions that are somewhat related, namely gastro esophageal reflux disease, which from

The Frequency of Gastroesophageal Reflux Disease in Nutcracker Esophagus and the Effect of Acid-Reduction Therapy on the Motor Abnormality

OTC PPI Therapy in Frequent Heartburn

Transesophageal Endoscopic Therapies for Gastroesophageal Reflux Disease

Key Words Gastroesophageal reflux; Gastrointestinal motility; Proton pump inhibitors; Therapeutics

Heartburn, also referred to acid reflux, happens when stomach acid flows back (refluxes) into your esophagus.

H o w d o e a c t. y o u r a c i

Alginates Extended Abstract

Gastroesophageal Reflux Disease (GERD)

SASKATCHEWAN REGISTERED NURSES ASSOCIATION

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

GERD 치료최신지견및 P-CAB 의역할 성균관대학교의과대학삼성서울병원소화기내과이준행

Prior Authorization Review Panel MCO Policy Submission

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Review article: pharmacology of esomeprazole and comparisons with omeprazole

Review article: management of mild and severe gastro-oesophageal reflux disease

Sustained improvement in symptoms of GERD and antisecretory drug use: 4-year follow-up of the Stretta procedure

Disclosures. Gastroesophageal Reflux Disease. Gastroesophageal Reflux Disease

Interventional procedures guidance Published: 16 December 2015 nice.org.uk/guidance/ipg540

ORIGINAL ARTICLE. Abstract

Philadelphia College of Osteopathic Medicine. Shawn P. Mahoney Philadelphia College of Osteopathic Medicine,

Original Policy Date

PPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)

Transcription:

GERD: 2014 Dilemmas and Solutions Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University

How to Maximize Your PPI Treatment? Improve compliance and adherance Fass R. Am J Gastroenterol. 2012 ;107(4):531-3.

GERD A Symptom Driven Disease I have heartburn I will take my medication Fass et al. Aliment Pharmacol Ther 2005;22(2):79-94.

Factors that may Adversely Affect Patients Compliance with PPI Therapy Knowledge about the treated disorder Desire for personal control The prescribed drug Perceived severity of symptoms Side effects Number of pills per day Additional medications Age Personality Socioeconomic status and healthcare coverage Fass et al. Aliment Pharmacol Ther 2005;22(2):79-94.

Time Consumption of a PPI In many Asian countries PPI s are taken after a meal Nexium 40 mg before dinner 40 mg at bedtime 24 hours Daytime Nighttime Percentage of time with intragastric ph>4 Median ph Percentage of time with intragastric ph>4 Median ph Percentage of time with intragastric ph>4 Median ph 59.5 4.4 52.3 4.1 70.6 4.8 55.2 4.2 50.6 3.9 60.5 5.2 Wilder-Smith C et al. Aliment Pharmacol Ther 2010;32:1249-

How to Maximize Your PPI Treatment? Split the Dose! Fass R. Am J Gastroenterol. 2012 ;107(4):531-3.

Mean Pharmacodynamic Findings of Different Esomeprazole Regimens (Per-Protocol Population, N=33) Percentage of time with intragastric ph>4 24 hour Daytime Nighttime Median ph Percentage of time with intragastric ph>4 Median ph Percentage of time with intragastric ph>4 Median ph 20 mg before breakfast 56.5 4.3 68.5 4.6 39.8 3.4 20 mg before dinner 46.3 3.8 46.6 3.7 46.8 3.8 20 mg twice daily 76.5 4.9 86.4 5.0 62.8 4.6 40 mg before breakfast 68.8 4.8 80.9 4.9 51.4 4.3 40 mg before dinner 59.5 4.4 52.3 4.1 70.6 4.8 40 mg at bedtime 55.2 4.2 50.6 3.9 60.5 5.2 40 mg twice daily 87.1 5.2 91.4 5.2 81.0 5.2 Wilder-Smith C et al. Aliment Pharmacol Ther 2010;32:1249-1256

Median intra-gastric ph The Effect of Different Dosing of Rabeprazole on Intra-Gastric ph 6.6 5.7 4.8 40MG QD 20MG BID 10MG QID Rabeprazole Dose Sugimoto et al. Aliment Pharmacol Ther. 2012 Oct;36(7):627-34.

How to Maximize Your PPI Treatment? The more the merrier! Fass R. Am J Gastroenterol. 2012 ;107(4):531-3.

Endoscopically Confirmed Healing Rates of Refractory Reflux Esophagitis after 8 weeks of Treatment Kinoshita et al. Am J Gastroenterol 2012;107:522-30.

Kinoshita et al. Am J Gastroenterol 2012;107:522-30.

% of patients Doubling the PPI Dose Versus Adding Placebo in Patients who Failed PPI once daily Double Blind, Randomized, Placebo-Controlled, 6-Week Trial 80 70 Comparison of the % of patients without any symptom during the last week of treatment P=NS 60 50 40 30 20 10 0 Daytime heartburn Nighttime heartburn acid regurgitation Rabeprazole 20mg + placebo (N=55) Rabeprazole 20mg BID (N=59) Hershcovici T et al. DDW 2013

% Reduction Doubling the PPI Dose Versus Adding Placebo in Patients who Failed PPI once daily Double Blind, Randomized, Placebo-Controlled, 6-Week Trial 80 70 Comparison of % reduction in symptom score, pre and post treatment, between the 2 patient groups P<0.01 60 50 40 30 20 10 0 Daytime heartburn Nighttime heartburn acid regurgitation Rabeprazole 20mg + placebo (N=55) Rabeprazole 20mg BID (N=59) Hershcovici T et al. DDW 2013

Mean number of days with <1 Doubling the PPI Dose Versus Adding Placebo in Patients who Failed PPI once daily Double Blind, Randomized, Placebo-Controlled, 6-Week Trial Comparison of the mean number of days, during the last week of treatment, with symptom intensity score <1, between the 2 patient groups 6.8 6.6 6.4 6.2 6 5.8 5.6 5.4 5.2 Daytime heartburn Nighttime heartburn acid regurgitation Rabeprazole 20mg + placebo (N=55) Rabeprazole 20mg BID (N=59) Hershcovici T et al. DDW 2013 P=0.04

How to Maximize Your PPI Treatment? One PPI Does not fit all Fass R. Am J Gastroenterol. 2012 ;107(4):531-3.

Percentage of Patients Symptomatically controlled on twice daily PPI Who were Successfully Stepped-Down to Dexlansoprazole Once Daily Fass R et al. Clin Gastroenterol Hepatol. 2012 Mar;10(3):247-53 In 88% (95% CI, 82.7%-93.4%; n=125) of the patients their heartburn remained well controlled after stepping down to once daily Dexlansoprazole 30mg MR.

Percentage of Patients who Remained Well Controlled after Stepping Down to Dexlansoprazole MR 30 mg by Prior PPI Prior PPI % of patients who remaining well controlled, % (n/n) Esomeprazole 84.0 (21/25) Lansoprazole 85.7 (12/14) Omeprazole 88.1 (74/84) Pantoprazole 100.0 (14/14) Rabeprazole 87.5 (7/8) Fass R et al. Clin Gastroenterol Hepatol. 2012 Mar;10(3):247-53

How to Improve Nighttime GERD- Related Symptoms?

Breakthrough Nighttime Symptoms on PPI Once Daily Consider Giving PPI Before Dinner No breakthrough symptoms, 62% During sleep 28 Breakthrough symptoms, 38% At night 65 Mid day 45 In the morning 16 N=1064 American Gastroenterology Association. GERD Patient Study: Patients and Their Medications. Harris Interactive Inc; 2008.

Therapeutic options for Nighttime GERD Avoid eating at least 3 hours prior bedtime Elevate the head of the bed Avoid the R decubitus position in bed Turn off lights when enter bed and minimize disturbances to a normal sleep Treat with a PPI and if symptoms are primarily during nighttime - give before dinner Split PPI dose (am and pm before a meal) Add H2RA, carafate, gaviscon etc. before bedtime Consider non-medical treatment Fujiwara Y et al. J Gastroenterol 2012:47:760-9.

Ramelteon Consider for Nighttime GERD Non-Scheduled hypnotic A selective MT1 and MT2 agonist Pharmacological structure close to omeprazole ( crude omeprazole ) Reduce Acid secretion and improve sleep Lokesh Jha et al DDW 2012 Nighttime heartburn Daytime heartburn *p<0.05

What is the Role of the Acid Pocket?

The Acid Pocket The Acid Pocket

3D Reconstruction of MR Images Showing Gaviscon Raft Forming a Mechanical Barrier Patient in the R Lateral Position EGJ Gaviscon Fox M et al. DDW 2011

How to Maximize your Treatment of NERD Patients? Maximal response to treatment may require more than 4 weeks.

Treatment Comparison between Placebo and PPI Once Daily in NERD Patients (Pooled Difference in Proportion with Heartburn Resolution by Time) Dean et al. Clin Gastroenterol Hepatol 2004;2:656-664

How to Maximize your Treatment of NERD Patients? Maximal response to treatment may require more than 4 weeks Complete resolution of symptoms an unrealistic clinical endpoint

Patient (%) Percentage of NERD Patients Reporting Complete Resolution of Heartburn after 4 Weeks of Treatment with Esomeprazole 40mg, Esomeprazole 20mg or Placebo 60 50 40 30 20 33.1 * * * 41.6 33.9 36.4 * Esomeprazole 40mg Esomeprazole 20mg Placebo 10 0 13.7 11.9 Study 1 Study 2 * P < 0.001 vs. placebo N = 123 121 124 118 113 118 Katz et al. Aliment Pharmacol Ther 2003:18(9):875-882.

Mean Percentage of Heartburn-free Days during 4 Weeks of Treatment with Esomeprazole 40mg, Esomeprazole 20mg or Placebo in NERD Patients Days hearburn -free (%) 80 70 60 50 40 30 20 10 0 62.8 * * 62.7 46.4 66.4 68.0 Study 1 Study 2 * * 36.2 Esomeprazole 40mg Esomeprazole 20mg Placebo * P 0.001 vs. placebo N = 115 112 117 114 102 106 Katz et al. Aliment Pharmacol Ther 2003:18(9):875-882.

% patients Expectations Proportion of NERD Patients Responding to Treatment at 4 Weeks 80 60 Omeprazole 20mg Omeprazole 10mg Placebo 61 46 49 40 31 24 20 13 0 Complete absence of heartburn Resolution of heartburn Lind et al. Scand J Gastroenterol 1997 Maradey-Romero C and Fass R, J Clin Gastroenterol 2014 N = 509

Treatment Comparison between Placebo and PPI Once Daily in NERD Patients (Pooled Difference in Proportion with Heartburn Resolution by Time) Dean et al. Clin Gastroenterol Hepatol 2004;2:656-664 - Sufficient - Complete

How to Maximize your Treatment of NERD Patients? Maximal response to treatment may require more than 4 weeks Completer resolution of symptoms an unrealistic clinical endpoint A growing recognition of new functional esophageal and extraesophageal disorders

New Functional Esophageal and Extra-Esophageal Disorders Hypersensitive esophagus Functional regurgitation Chronic Cough Throat clearing Throat Burning/Pain The burning mouth syndrome

What are the Non-Medical Interventions for GERD?

Recent Trends in Treatment Development for GERD Non-medical techniques Drug Development

The Rate of Antireflux Procedures Using the Nationwide Inpatient Sample Year Wang YR et al. Dis Esoph 2011;24:215-23

The Stretta Technique

The Stretta Technique

A Randomized, Double-blinded, Sham- Controlled Trial (STRETTA) Sham (25) Active (31) P value Heartburn -0.6-1.6.01 GERD-HQRL -3-13.003 SF-36 1 7.05 Daily PPI -29% -46%.9 Median 24-pH <4-1.5-1.8.79 Median LESP 2.5 16.2.72 Esophageal erosion 2% 8%.88 Corley DA et al. Gastroenterology 2003;125:668-676

Noar M Surg Endosc 2014 (in press)

Esophyx

Three-year Results of a Multicenter Prospective Study of Transoral Incisionless Fundoplication N = 66 GERD-HRQL 4 25 (off PPI) 9 (on PPI) Discontinuation of Daily PPI Normalization of esophageal ph 61% (ITT) 74% (PP) 39% (ITT) 82% (PP) 18.2% underwent revisional procedures Muls V et al Surg Innov 2013;20:321-30

LINX Reflux Management System Reinforces the LES restoring the barrier function Expands during swallow allowing food to enter stomach Highest Magnetic Resistance Lowest Magnetic Resistance

The Angelchick

Are We Close for a Concierge Service for GERD?

Can we Individualize GERD Treatment at the Physiological Level? The Future! Wireless External Programmer Implantable Pulse Generator (IPG) + Bipolar Leads Investigational device, currently not FDA approved or CE Marked

EndoStim Implant Investigational device, currently not FDA approved or CE Marked

The Long-Term Effect of EndoStim on HRQL (n=24) 25 20 Median composite GERD-HRQL scores 23.5 15 10 5 0 9 4 2 2 2 Median composite GERD-HRQL scores Rodriguez L et al. endoscopy 2013;45:595-604

Rodriguez L et al. endoscopy 2013;45:595-604 The Long-Term Effect of EndoStim on Intra-Esophageal Acid Exposure (n=24) 12 10 Median % 24-h Distal Esophageal ph < 4.0 10.1 8 6 4 2 6.3 5.1 3.3 0 Baseline Month 3 Month 6 Month 12 Median % 24-h Distal Esophageal ph < 4.0

Heart Burn The End